Nicox Provides First Half 2025 Financial Results

Press ReleaseNicox Provides First Half 2025 Financial Results  New Drug Application (NDA) submissions for NCX 470 expected in 2026 in the U.S. and ChinaCompany believes that it can finance its existing operations for at least 12 months and expects to fully repay existing financial debts in 2026October 23, 2025 – release at 7:30 am CETSophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today...

Biot, 23/10/2025 (informazione.news - comunicati stampa - salute e benessere)

 

 

Attachment